Cancer Vaccines Market Growth Factors with Key Drivers Forecast From 2019-2026 | Industry Analysis By Key Players, And Upcoming Trends

Cancer is the second leading cause of morbidity and mortality worldwide. Gene mutation is a major cause of cancer. The disease can also be caused by inherited genes. Cancer can be divided into carcinoma, lymphomas, leukaemias, brain tumors, and sarcomas based on the type of cell the disease initiates in. According to World Health Organization (WHO), 2017, nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income countries. Moreover, it is projected that for next two decades, 70% of new cases are expected to be diagnosed globally. Development of cancer vaccines can aid in substantially decreasing the number of cancer cases.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/1209

Global Cancer Vaccines Market Taxonomy:

By Product Type:

• Preventive cancer vaccines
• Therapeutic cancer vaccines

By Technology:

• Subunit Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Recombinant Vector Vaccines
• Viral Vector And DNA Cancer Vaccines
• Others

By Application:

• Cervical cancer
• Prostate cancer
• Others

LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1209

Increasing approval and launch of new vaccines for the treatment of different types of cancers is expected to boost growth of the cancer vaccines market over the forecast period

Key players in the market are focused on adopting M&A and collaboration strategies in order to expand their product portfolio. For instance, in 2017, Gilead Science Inc. acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. In 2017, Treos Bio, collaborated with Pharmaceutical Product Development, LLC (PPD) to conduct its first-in-human clinical trial for its cancer vaccine for metastatic colorectal cancer.

Furthermore, BioNTech developed RNA vaccines for mutations caused due to cancer. RNA vaccine exposes cancer cell to antigen, which is recognized by the immune system. On the other hand, Scancell’s DNA vaccine forces cancerous cell to express two antigens – gp100 and TRP-2 stimulating a strong T cell response.

In 2017, Jonsson Comprehensive Cancer Center and the Brain Tumor Center at the University of California Los Angeles (UCLA), was designated a Specialized Program of Research Excellence (SPORE) by the National Cancer Institute. The program is expected to support research into prevention, detection, and treatment of cancers and will promote co-operation among scientist in different disciplines, and also help to translate basic research from laboratories to clinical trials more quickly and effectively. Such recognition by national organizations is expected to support research in cancer vaccines.

According to a research from University of Pittsburgh School of Medicine, in 2017, a high dose flu vaccine can be used to treat people aged between 54–64 years with chronic condition such as heart disease, lung disease, diabetes, and cancer. The study is recommended for clinical trials in geriatric population.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/cancer-vaccines-market-1209

Also, in 2017, Swiss Biotech, developed VXM01 — an attenuated bacterial vaccine modified to express vascular endothelial growth factor receptor-2 (VEGFR2), stimulates cytotoxic (killer) T cells, which will destroy cells in the vasculature feeding tumor and allow greater infiltration of immune cells. This vaccine is expected to be used for treatment in colorectal cancer and glioblastoma.

In August 2017, Imugene Limited announced the entry of its anti-cancer vaccine, HER-Vaxx for gastric cancer in 1b/2 clinical study and the phase 2 is expected to start soon.

Increasing prevalence and incidence of different cancers is expected to favor growth of the cancer vaccines market

According to WHO, in 2015, about 8.8 million people died from cancer. Moreover, tobacco related cancers was responsible for 22% deaths, lung cancer accounted for 1.69 million deaths, liver cancer led to 788,000 deaths. Colorectal, stomach, and breast cancer are estimated to cause 774,000, 754,000, and 571,000 deaths, worldwide. Increasing prevalence is a major driving factor to fuel growth of the cancer vaccines market.

Key players in the global cancer vaccines market include, Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

Other Related Reports:

Cervical Cancer Vaccines Market, By Product Type, By Distribution Channel, and By Region – Size, Share Trends, and Forecast 2018 – 2026

Dendritic Cell and Tumor Cell Cancer Vaccines Market, by Antigen, by Application, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Peptide Cancer Vaccine Market, by Pipeline Phase, by Application, and by Region – Global Insights, Industry Trends, Outlook, and Opportunity Analysis, 2018-2026

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.